-
公开(公告)号：US20240299388A1
公开(公告)日：2024-09-12
申请号：US18572404
申请日：2022-06-23
申请人： Erasca, Inc.
发明人： Robert Field SHOEMAKER , Erin Denise LEW , Wei LIN , Leslie Harris BRAIL , Leenus MARTIN , Jingchuan ZHANG , Joanne OH
IPC分类号： A61K31/506 , A61K31/497 , A61K31/519 , A61K31/5383 , A61K39/395 , A61K45/06 , A61P35/00
CPC分类号： A61K31/506 , A61K31/497 , A61K31/519 , A61K31/5383 , A61K39/3955 , A61K45/06 , A61P35/00
摘要： The present disclosure relates generally to the use an ERK1/2 inhibitor in combination with a SHP2 inhibitor for treating cancer, specifically solid tumors.
-
32.发明公开公开(公告)号：US20240299386A1
公开(公告)日：2024-09-12
申请号：US18571331
申请日：2022-08-16
发明人： Jung-Mi Hah , Joon Hong Jun , Ji Hyun Baek
IPC分类号： A61K31/506 , C07D401/14 , C07D403/14 , C07D405/14
CPC分类号： A61K31/506 , C07D401/14 , C07D403/14 , C07D405/14
摘要： The present invention relates to: a novel imidazole derivative compound; and isomer thereof or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition comprising same. The imidazole derivative compound according to the present invention exhibits selective inhibitory activity against JNK, particularly JNK3, and thus can be used as a pharmaceutical composition for use in preventing and treating degenerative brain diseases (degenerative brain diseases including dementia of Alzheimer's type dementia and Parkinson's disease).
-
公开(公告)号：US20240299383A1
公开(公告)日：2024-09-12
申请号：US18205628
申请日：2023-06-05
发明人： Pan LI , Limin JIA , Zhiyong QIN , Zhaoyang WANG
IPC分类号： A61K31/506 , A61P37/04 , C07K16/28
CPC分类号： A61K31/506 , A61P37/04 , C07K16/2818 , C07K16/2827
摘要： The present invention discloses the inhibitory effect of azvudine as an immunomodulator on mice bearing CT-26 tumor. It is found that azvudine has no significant anti-tumor effect on immunodeficient B-NDG mice bearing CT-26 tumor, yet has an antitumor effect on BALB/c mice with normal immunity bearing CT-26 tumor model. The present invention further studies the combined effect of azvudine and PD-1 antibody, and finds that compared with a single drug, the combined administration has a synergistic anti-tumor effect.
-
公开(公告)号：US12083118B2
公开(公告)日：2024-09-10
申请号：US16982842
申请日：2019-03-29
发明人： Yingzhi Bi , Bruce D. Dorsey , Yi Fan , Christopher Brooks Moore , Duyan Nguyen
IPC分类号： A61K31/506 , A61K31/137 , A61K31/277 , A61K31/4164 , A61K31/444 , A61K31/445 , A61K31/4545 , A61K31/505 , A61K45/06 , C07C217/58 , C07C255/61 , C07D211/60 , C07D233/26 , C07D239/06 , C07D401/12 , C07D401/14
CPC分类号： A61K31/506 , A61K31/137 , A61K31/277 , A61K31/4164 , A61K31/444 , A61K31/445 , A61K31/4545 , A61K31/505 , A61K45/06 , C07C217/58 , C07C255/61 , C07D211/60 , C07D233/26 , C07D239/06 , C07D401/12 , C07D401/14
摘要： The present invention includes substituted 3,3′bis(phenoxymethyl)-1,1′-biphenyl compounds, analogues thereof, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient.
-
公开(公告)号：US20240294505A1
公开(公告)日：2024-09-05
申请号：US16485049
申请日：2018-02-02
发明人： Ilona GUTCHER , Ulrike RÖHN , Norbert SCHMEES , Ludwig ZORN , Lars RÖSE , Benjamin BADER , Christina KOBER , Rafael CARRETERO , Detlef STÖCKIGT , Horst IRLBACHER , Michael PLATTEN
IPC分类号： C07D403/04 , A61K31/501 , A61K31/506 , A61K45/06 , A61P35/00 , C07D237/14 , C07D401/04 , C07D401/14 , C07D405/14 , C07D409/04 , C07D409/14 , C07D413/04 , C07D417/04
CPC分类号： C07D403/04 , A61K31/501 , A61K31/506 , A61K45/06 , A61P35/00 , C07D237/14 , C07D401/04 , C07D401/14 , C07D405/14 , C07D409/04 , C07D409/14 , C07D413/04 , C07D417/04
摘要： The present invention covers 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamide compounds of general formula (I), in which X, R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.
-
36.发明公开公开(公告)号：US20240293461A1
公开(公告)日：2024-09-05
申请号：US18583096
申请日：2024-02-21
发明人： Rachel Lynn , Crystal Mackall , Tom J. Wandless , Evan Weber
IPC分类号： A61K35/17 , A61K31/5025 , A61K31/506 , A61P35/00 , C07K14/705 , C07K14/725 , C07K16/30 , C12N5/0783 , C12N9/90
CPC分类号： A61K35/17 , A61K31/5025 , A61K31/506 , A61P35/00 , C07K14/7051 , C07K14/70521 , C07K14/70578 , C07K16/3084 , C12N5/0636 , C12N9/90 , C07K2317/622 , C07K2319/02 , C07K2319/03 , C07K2319/33 , C12N2501/727 , C12N2510/00
摘要： The present invention relates to T cell compositions and methods of using the same in the context of therapy and treatment. In particular, the invention provides chimeric antigen receptor (CAR) T cells that are modified to maintain functionality under conditions in which unmodified CAR T cells display exhaustion. Compositions and methods disclosed herein find use in inhibiting or reversing CAR T cell exhaustion (e.g., by modulating CAR surface expression) thereby enhancing CAR T cell function. Compositions and methods of the invention find use in both clinical and research settings, for example, within the fields of biology, immunology, medicine, and oncology.
-
公开(公告)号：US20240293432A1
公开(公告)日：2024-09-05
申请号：US18594989
申请日：2024-03-04
发明人： Subhra MOHAPATRA , Shyam MOHAPATRA , Ryan Green
IPC分类号： A61K31/00 , A61K31/506 , A61K31/519 , A61K31/5377 , A61P35/00
CPC分类号： A61K31/658 , A61K31/506 , A61K31/519 , A61K31/5377 , A61P35/00
摘要： A composition including a cannabinoid and an anti-cancer agent and methods of treating lung cancer using said composition.
-
公开(公告)号：US20240293419A1
公开(公告)日：2024-09-05
申请号：US18478483
申请日：2023-09-29
发明人： Heike KEILHACK , Roberto Pili
IPC分类号： A61K31/5377 , A61K31/404 , A61K31/44 , A61K31/4412 , A61K31/444 , A61K31/496 , A61K31/506 , A61K31/517 , A61K45/06 , A61P35/00
CPC分类号： A61K31/5377 , A61K31/404 , A61K31/44 , A61K31/4412 , A61K31/444 , A61K31/496 , A61K31/506 , A61K31/517 , A61K45/06 , A61P35/00
摘要： The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents (such as tyrosine kinase inhibitors or VEGF/VEGFR inhibitors), particularly anticancer agents such as sunitinib, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
-
![(1H-PYRROLO[2,3-B]PYRIDIN-1-YL)PYRIMIDIN-2-YL-AMINO-PHENYL-ACRYLAMIDE INHIBITORS OF EGFR FOR USE IN THE TREATMENT OF BRAIN TUMORS](/abs-image/US/2024/09/05/US20240293405A1/abs.jpg.150x150.jpg)
39.发明公开公开(公告)号：US20240293405A1
公开(公告)日：2024-09-05
申请号：US18573473
申请日：2022-06-22
发明人： Jean J. Zhao , William Kerns
IPC分类号： A61K31/506 , C07D471/04
CPC分类号： A61K31/506 , C07D471/04
摘要： The invention generally relates to pharmaceuticals and therapeutic methods. More particularly, the invention provides small molecule EGFR inhibitors (e.g., EGFR tyrosine kinase inhibitor compounds) and pharmaceutical compositions thereof, as well as methods of their use in treating various diseases and conditions, such as cancers of the central nervous system (e.g., primary and metastatic brain cancers) and lung cancers.
-
公开(公告)号：US20240293403A1
公开(公告)日：2024-09-05
申请号：US18570297
申请日：2022-06-16
申请人： Telios Pharma, Inc.
发明人： Wayne Rothbaum
IPC分类号： A61K31/506 , A61K31/497 , A61K31/519 , A61K31/5377 , A61K45/06
CPC分类号： A61K31/506 , A61K31/497 , A61K31/519 , A61K31/5377 , A61K45/06
摘要： Therapeutic methods and pharmaceutical compositions for treating symptoms associated with myeloproliferative neo-plasms in a human subject are described. In certain embodiments, the disclosure includes therapeutic methods of treating symptoms associated with myeloproliferative neoplasms using a BTK inhibitor.
-
-
-
-
-
-
-
-
-
搜索结果
13999 条记录 (耗时 0.037 秒)
